参白扶正颗粒与阿帕替尼联合治疗胃癌的临床疗效及对体内免疫微环境的影响  

Clinical efficacy of Shenbai Fuzheng granules combined with apatinib in the treatment of gastric cancer and its impact on the immune microenvironment in vivo

作　　者：杨丙雨 谈丽彩 陈建华 YANG Bingyu;TAN Licai;CHEN Jianhua(Department of Tumor 5,Handan Hospital of Integrated Chinese and Western Medicine,Handan 056001,China)

机构地区：[1]河北省邯郸市中西医结合医院肿瘤五科,邯郸056001

出　　处：《中国临床药学杂志》2024年第8期593-598,共6页Chinese Journal of Clinical Pharmacy

摘　　要：目的探讨参白扶正颗粒与阿帕替尼治疗胃癌的临床疗效及对体内免疫微环境的影响。方法选取2021年10月至2023年10月医院收治的144例胃癌患者作为研究对象,按照随机数字表法分为研究组和对照组,每组72例。对照组给予阿帕替尼治疗,研究组给予参白扶正颗粒联合阿帕替尼治疗,分析2组患者治疗前后免疫因子、中医证候积分、治疗效果和不良反应情况。结果与治疗前相比,治疗后2组癌胚抗原(CEA),糖类抗原(CA199、CA724),癌抗原(CA125),白细胞介素-6(IL-6)及白细胞介素-10(IL-10)明显降低,CD4^(+)、CD3+、NK细胞、IFN-γ、TNF-α、CD4^(+)/CD8^(+)明显增加,且研究组上述指标水平变化更显著(P<0.05);研究组腹胀、纳差、乏力、便溏评分均明显降低,对照组胃痛、消瘦评分均明显降低(P<0.05);治疗后研究组乏力、胃痛、纳差、便溏较对照组明显改善(P<0.05);近期疗效结果显示研究组总有效率显著高于对照组(48.61%vs 31.94%),肝功能损伤、消化道症状、贫血、白细胞降低发生率及严重程度均较对照组显著降低(P<0.05)。结论采用参白扶正颗粒联合阿帕替尼联合治疗胃癌,能够影响患者体内免疫微环境变化,调节免疫功能,抑制机体炎性反应,具有较好的疗效,且不良反应较轻。AIM To explore the clinical efficacy of Shenbai Fuzheng granules combined with apatinib in the treatment of gastric cancer and its impact on the immune microenvironment in vivo.METHODS A total of 144 gastric cancer patients admitted to the hospital from October 2021 to October 2023 were selected as the research subjects.They were randomly divided into study group and control group using a random number table method,with 72 patients in each group.The control group was treated with apatinib,while the study group was treated with Shenbai Fuzheng granules combined with apatinib.Immune factors,traditional Chinese medicine syndrome scores,treatment effects,and adverse reactions of 2 groups of patients were analyzed before and after treatment.RESULTS Compared with prior treatment,levels of carcinoembryonic antigen(CEA),carbohydrate antigen(CA199,CA724),cancer antigen(CA125),interleukin 6(IL-6),and interleukin 10(IL-10)in both groups after treatment decreased significantly,while levels of CD4^(+),CD3~+,NK cells,IFN-γ,TNF-α,and CD4^(+)/CD8^(+)increased significantly.Moreover,levels of these indicators in the study group showed more significant changes(P<0.05).Scores of bloating,poor appetite,fatigue,and loose stools in the research group were significantly reduced compared to prior treatment,while the scores of stomach pain and weight loss in the control group were significantly reduced(P<0.05).After treatment,the study group showed significant improvement in fatigue,stomach pain,poor appetite,and loose stools compared to the control group(P<0.05).Recent efficacy results showed that the total effective rate of the study group was significantly higher than that of the control group(48.61%vs 31.94%),and the incidence and severity of liver function damage,digestive symptoms,anemia,and leukopenia were significantly reduced compared to the control group(P<0.05).CONCLUSION The combination of Shenbai Fuzheng granules and apatinib in the treatment of gastric cancer can affect the changes in the immune microenvironment of patien

关 键 词：阿帕替尼 参白扶正颗粒 胃癌 免疫微环境 疗效 

分 类 号：R735.2[医药卫生—肿瘤]